
|Articles|September 12, 2013
Medical Economics Careers e-newsletters
Advertisement
Aug. 15, 2013
Aug. 22, 2013
Aug. 29, 2013
Sept. 5, 2013
Sept. 12, 2013
Advertisement
Related to this article


The decision leaves the FDA under acting leadership as Senate Republicans race to confirm nominees before Democrats take control in January.

Starting Jan. 1, Medicare will pay 20% less for the lower-valued service when an office visit billed with modifier 25 falls on the same day as a zero-day global procedure. One claims report priced at local 2027 rates shows independent practices their exposure, and three documentation habits protect the visits that still qualify for full payment.

The Commerce Department’s Section 232 investigation could bring new tariffs on imported medical devices and supplies. Targeted reserves, procurement preferences and a faster FDA pathway for switching to U.S. suppliers would do more to bring device manufacturing home.

Retired physicians who rely on monthly portfolio withdrawals risk selling low in a downturn. Here's how income investments such as preferred stocks, REITs and options-based ETFs can cover living costs and leave growth assets untouched.

The virtual program gives physicians practical, expert-led sessions on strengthening their practices' finances and their own careers.

If artificial intelligence improves medicine, what does that mean for malpractice insurance premiums?
Advertisement
Advertisement
Trending on Medical Economics
1
How to calculate what Medicare’s 2027 modifier 25 cut will cost your practice
2
The precipice of real AI-driven change in health care: What it means for outcomes and risk
3
White House withdraws Heidi Overton's FDA nomination on eve of Senate committee vote
4
Why medical device tariffs would hurt the U.S. manufacturers they’re meant to help
5


